Search Results

You are looking at 11 - 20 of 127 items for :

  • "genetic counseling" x
  • Refine by Access: All x
Clear All
Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel

applying these guidelines to individual families. Furthermore, these guidelines were not developed as a substitute for professional genetic counseling. Rather, they are intended to help health care providers identify individuals who may benefit from cancer

Full access

Kenneth Offit

,” Dr. Offit stated at the outset of his talk. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in

Full access

Michael J. Hall, Andrea D. Forman, Robert Pilarski, Georgia Wiesner, and Veda N. Giri

inherited cancer risk when first-line evaluation has been inconclusive All discussions must include the risks and benefits of gene panel testing in a genetic counseling setting, with informed consent reflecting the discussion. Choice of Laboratory

Full access

Heather H. Cheng, Alexandra O. Sokolova, Edward M. Schaeffer, Eric J. Small, and Celestia S. Higano

actionability of widespread genetic testing in early, low-risk prostate cancer settings without other risk factors remain unclear, and short-term unintended consequences include clinical confusion and low-yield depletion of limited genetic counseling resources

Full access

Michael J. Hall

, and by whom consent would be obtained in a population screening program remain unanswered. 7 , 9 , 13 Low provider knowledge of MSI/IHC and scarce genetic counseling resources 14 would likely leave many patients poorly informed about the

Full access

Monique A. de Bruin, James M. Ford, and Allison W. Kurian

bilateral breast cancer at a young age, she met NCCN criteria for BRCA1/2 mutation testing. 1 She underwent appropriate genetic counseling and then BRCA1/2 mutation testing by full sequencing, which was negative. BRCAnalysis Comprehensive Rearrangement

Full access

Thai H. Ho and Eric Jonasch

testing of selected genes based on renal cell carcinoma (RCC) histology: (A) clear cell, (B) papillary type I, (C) papillary type II, and (D) chromophobe. Persons with RCC aged 46 years or younger should be considered for genetic counseling and germline

Full access

Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor

for genetic counseling, which revealed no family history of hereditable cancer. Plasma was sent for cell-free DNA (cfDNA) sequencing. 7 A baseline staging CT scan was obtained before the planned initiation of gemcitabine and nanoparticle albumin

Full access

Heather Bowers, Kerri Susko, Aniket Saha, and Elizabeth Cull

Background: Adolescent and young adult (AYA) oncology patients have a distinctive set of needs that are often not addressed by primary providers in busy clinical practices. Genetic counseling, fertility preservation, clinical trial enrollment, and

Full access

Patrick M. Lynch

Individuals with a family history of colorectal cancer or colorectal adenomas have an increased risk for colorectal cancer. When no hereditary syndrome is evident, screening is based on empiric risk estimates. The risk is greatest for individuals with specific inherited cancer-predisposing disorders. When conditions such as familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer are diagnosed, specific neoplasm risk estimates can usually be performed based on advances in molecular genetics. These estimates lead to more straightforward and cost-effective approaches to surveillance and management. The National Comprehensive Cancer Center Network (NCCN) and other groups have provided detailed guidelines for evaluating patients based on recognition of clinical syndrome characteristics, followed by appropriate genetic counseling, genetic testing, and optimal surveillance. The NCCN guidelines are used as a frame of reference for this discussion of selected recent advances in human cancer genetics as they apply to clinical practice.